Investor Presentaiton
For personal use only
1. Imaging and Robotics in Surgery Alliance with Mauna Kea Technologies.
Telix Pharmaceuticals Limited (ASX: TLX)
Our long-term vision for prostate cancer
Improving access, imaging and treatment options for patients
Further development of the PSMA target underpins our lifecycle
management strategy for prostate cancer and vision to improve
patient outcomes
PSMA pipeline includes imaging, therapy and surgical tools
•
•
NOBLE Registry (PSMA-SPECT tracer): TLX599-CDx
(99mTc-iPSMA) - PSMA imaging access for patients in
developing and remote areas, where PET is not readily
available
Next-generation alpha therapy: TLX592 (225AC-
RADmAbⓇ) - high potency, complementary to TLX591
Image guided surgery: TLX591-Sx (68Ga-PSMA-IRDye) -
dual-labelled PET-optical tracer for image guided surgery,
enables real-time cancer detection1
TELIX
PHARMACEUTICALS
35
55View entire presentation